share_log

BioLife Solutions Announces the Divestiture of Its Stirling Freezer Business

BioLife Solutions Announces the Divestiture of Its Stirling Freezer Business

BioLife Solutions宣布剥离其斯特灵冷冻机业务
PR Newswire ·  04/18 20:05

BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling").

华盛顿州博塞尔,2024 年 4 月 18 日 /PRNewswire/ — 生物生命解决方案有限公司(纳斯达克股票代码:BLFS) (“BioLife” 或 “公司”)是为细胞和基因疗法(“CGT”)及更广泛的生物制药市场提供生物生产产品和服务的领先开发商和供应商,今天宣布,它已完成对其全资子公司环球制冷公司(“GCI” 或 “斯特林”)的剥离。

Roderick de Greef, Chairman and CEO, commented, "After a thorough and extensive process, we're pleased to have completed the divestiture of the Stirling freezer business. The sale is expected to immediately eliminate several million dollars of quarterly cash burn and removes product warranty liabilities, which totaled $7.5 million as of December 31, 2023. Most importantly, we anticipate that this transaction will result in higher growth rates in total revenue and adjusted EBITDA, as well as gross margin expansion."

董事长兼首席执行官罗德里克·德格里夫评论说:“经过彻底而广泛的过程,我们很高兴完成了斯特灵冷冻机业务的剥离。此次出售预计将立即消除季度数百万美元的现金消耗,并取消截至2023年12月31日总额为750万美元的产品保修负债。最重要的是,我们预计这笔交易将提高总收入和调整后的息税折旧摊销前利润的增长率,以及毛利率的扩大。”

The transaction, which is structured as a stock sale, required $7 million in cash to remain on the balance sheet of GCI and the repayment of $2.6 million in GCI long-term debt. BioLife Solutions intends to file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission containing the definitive agreement along with certain pro forma financial information.

该交易以股票出售的形式进行,需要700万美元的现金才能保留在GCI的资产负债表上,并偿还260万美元的GCI长期债务。BioLife Solutions打算向美国证券交易委员会提交一份表格8-K的最新报告,其中包含最终协议以及某些预计财务信息。

About BioLife Solutions

关于 BioLife 解决方案

BioLife Solutions is a leading supplier of cell processing tools and services for the CGT and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. For more information, please visit , and follow BioLife on LinkedIn and X.

BioLife Solutions是为CGT和更广泛的生物制药市场提供细胞处理工具和服务的领先供应商。我们的专业知识通过提供在收集、开发、储存和分发过程中保持生物材料健康和功能的解决方案,促进新疗法的商业化。欲了解更多信息,请访问并在 LinkedIn 和 X 上关注 BioLife。

Cautions Regarding Forward-Looking Statements

关于前瞻性陈述的注意事项

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed" and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

本新闻稿中包含的某些陈述不是历史事实,可能是1995年《私人证券诉讼改革法》所指的前瞻性陈述。诸如 “计划”、“期望”、“相信”、“预期”、“设计” 等词语和类似词语旨在识别前瞻性陈述。前瞻性陈述基于我们当前的预期和信念,涉及许多难以预测的风险和不确定性,可能导致实际结果与前瞻性陈述所陈述或暗示的结果存在重大差异。对其中某些风险、不确定性和其他事项的描述可以在我们向美国证券交易委员会提交的文件中找到,所有这些文件均可在www.sec.gov上查阅。由于前瞻性陈述涉及风险和不确定性,因此实际结果和事件可能与我们目前预期的结果和事件存在重大差异。提醒读者不要过分依赖这些前瞻性陈述,这些陈述仅代表截至本文发布之日。我们没有义务公开更新这些前瞻性陈述以反映在此之后发生的事件或情况,也没有义务反映其对这些前瞻性陈述的预期的任何变化或意外事件的发生。

Contact:

联系人:

Troy Wichterman
Chief Financial Officer
(425) 402-1400
[email protected]

特洛伊·威奇特曼
首席财务官
(425) 402-1400
[电子邮件保护]

SOURCE BioLife Solutions, Inc.

来源 Biolife Solutions, Inc.

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发